Advertisement
Organisation › Details
TxCell S.A. (Euronext Paris: TXCL)
TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, the TxCell's second drug candidate developed as a treatment for autoimmune uveitis, is expected to enter in clinical studies in the near future. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 47 employees. *
Start | 2001-01-01 splitoff | |
Predecessor | Inserm (National Institute for Health and Medical Research, FR) | |
Industry | ASTrIA technology (Antigen Specific Treg for Inflammation and Autoimmunity) | |
Industry 2 | ENTrIA technology (Engineered Treg for Inflammation and Autoimmunity) | |
Person | Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard) | |
Person 2 | Flipo, Raphaël (TxCell 201509 CFO) | |
Region | Valbonne | |
Country | France | |
Street | Allée de la Nertière Les Cardoulines HT1 | |
City | 06560 Valbonne – Sophia Antipolis | |
Tel | +33-4-9721-8300 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2017-12-31) |
Currency | EUR | |
Annual sales | 2,234,000 (revenue + other income (2017) 2017-12-31) | |
Profit | -10,911,000 (2016-12-31) | |
Cash | 4,910,000 (2017-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for TxCell S.A. (Euronext Paris: TXCL)
- [1] Sangamo Therapeutics, Inc.. (7/23/18). "Press Release: Sangamo Therapeutics to Acquire TxCell". Richmond, CA & Valbonne....
- [2] TxCell S.A.. (7/9/18). "Press Release: TxCell Exercises In-license Option to the University of British Columbia's Intellectual Property Rights of the HLA-A2 CAR-Treg Program". Valbonne....
- [3] TxCell S.A.. (6/21/18). "Press Release: First in Vivo Proof-of-Concept Data with CD8+ CAR-Treg Presented at FOCIS 2018". Valbonne....
- [4] TxCell S.A.. (5/31/18). "Press Release: TxCell Names Lonza as Its CAR-Treg Cellular Product Manufacturer". Valbonne & Basel....
- [5] TxCell S.A.. (4/25/18). "Press Release: TxCell – Financial Information for the 1st Quarter of 2018 and Availability of the 2017 Registration Document (document de référence)". Valbonne....
- [6] TxCell S.A.. (1/17/18). "Press Release: TxCell Obtains Government Funding to Advance Its Lead CAR-Treg Program". Valbonne....
- [7] TxCell S.A.. (12/18/17). "Press Release: TxCell Completes CAR-Treg Manufacturing Process Development and Provides Update to CMO Selection". Valbonne....
- [8] TxCell S.A.. (10/25/17). "Press Release: TxCell Renegotiates OCABSA Financing Option to Extend Cash Runway [Not for distribution in the United States of America, Canada, Australia and Japan]". Valbonne....
- [9] TxCell S.A.. (10/19/17). "Press Release: Financial Information for the 3rd Quarter of 2017". Valbonne....
- [10] TxCell S.A.. (7/26/17). "Press Release: TxCell – Financial Information for the 2nd Quarter of 2017". Valbonne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top